RT Journal Article
SR Electronic
T1 Large-scale deployment of SIT-based technology in a Brazilian city prevented Dengue outbreak
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2022.09.19.22279924
DO 10.1101/2022.09.19.22279924
A1 de Castro Poncio, Lisiane
A1 dos Anjos, Filipe Apolinário
A1 de Oliveira, Deborah A.
A1 Rosa, Aline
A1 Silva, Bianca Piraccini
A1 Rebechi, Débora
A1 da Costa Franciscato, Diego Alan
A1 de Souza, Cláudio
A1 Paiva, Uilson
A1 Mazurechen, Marilu
A1 de Araújo Ribeiro, Rafael
A1 Basile, Priscila
A1 Rezende, Erikon Leandro
A1 Paldi, Nitzan
YR 2022
UL http://medrxiv.org/content/early/2022/09/20/2022.09.19.22279924.abstract
AB Background Dengue is a global problem that seems to be worsening, as hyper-urbanization associated with climate change has led to a significant increase in the abundance and geographical spread of its principal vector, the Aedes aegypti mosquito. The current available solutions, including vaccines and traditional vector-control methods, have not been able to stop the spread of dengue which shows the urgent need to implement alternative technologies as practical solutions. We recently presented ‘Natural Vector Control’ (NVC), a new Sterile Insect Technology-based method that uses massive releases of sterile male mosquitoes produced from the combined treatment with dsRNA and thiotepa. In a previous pilot trial, two intervention periods over two epidemiological seasons were carried out, in which the control and treated areas were alternated between the epidemiological seasons, and we demonstrated the efficacy and safety of the method in suppressing the Ae. aegypti vector population and in blocking the occurrence of an outbreak of dengue in the treated areas. Here, we expand the use of the “Natural Vector Control” program in a large-scale 2-year period intervention carried out in an entire city located in southern Brazil.Methods Sterile male mosquitoes were produced from locally sourced Ae. aegypti mosquitoes by using a treatment that includes double-stranded RNA and thiotepa. Weekly massive releases of sterile male mosquitoes were performed in predefined areas of Ortigueira from December 2020 to July 2022. Mosquito monitoring was performed by using ovitraps during the entire period of intervention. Dengue incidence data in Ortigueira and neighboring cities was obtained from the Brazilian National Disease Surveillance system.Results During the two epidemiological seasons, the intervention in Ortigueira resulted in up to 98.7% suppression of live progeny of field Ae. aegypti mosquitoes recorded over time. More importantly, the program protected Ortigueira from a dengue outbreak that occurred in the neighboring cities: the dengue incidence in Ortigueira was 97% lower compared to 4 control cities.Conclusions The Natural Vector Control method has again been shown to be a safe and efficient way to suppress Ae. aegypti field populations and prevent the occurrence of a dengue outbreak. Importantly, it has been shown to be applicable for large-scale, real-life conditions.Competing Interest StatementAll authors have completed the ICMJE uniform disclosure form at www.icmje.org/coi_disclosure.pdf and declare: DACF and CS has no interest conflicts, FAA, LCP, AR, DAO, BP, DR are employees of Forrest Brasil Tecnologia Ltda.; UP, MM, RAR, PB and ELR are employees of Klabin and NP is employee of Forrest Innovations Ltd.Clinical TrialEnvironmental License Number 36127Funding StatementThis study was funded by Forrest Innovations and Klabin.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesI confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present work are contained in the manuscript